Effects of Campomanesia xanthocarpa on inflammatory processes, oxidative stress, endothelial dysfunction and lipid biomarkers in hypercholesterolemic individuals

被引:42
作者
Nazario Viecili, Paulo Ricardo [1 ,2 ]
Borges, Diego Olschowsky [2 ,3 ]
Kirsten, Karina [2 ]
Malheiros, Jenifer [2 ,4 ]
Viecili, Eduardo [2 ]
Melo, Rodolfo Dahlem [2 ]
Trevisan, Gabriela [4 ]
da Silva, Mariane Arnoldi [4 ]
Bochi, Guilherme Vargas
Moresco, Rafael Noal [5 ]
Klafke, Jonatas Zeni [1 ,2 ]
机构
[1] Univ Cruz Alta, Programa Posgrad Atencao Integral Saude, BR-98020290 Cruz Alta, RS, Brazil
[2] Inst Cardiol Cruz Alta, Ctr Ensino Pesquisa, BR-98010110 Cruz Alta, RS, Brazil
[3] Fundacao Univ Fed Ciencias Saude Porto Alegre, BR-90050170 Porto Alegre, RS, Brazil
[4] Univ Fed Santa Maria, Programa Posgrad Ciencias Biol Bioquim Toxicol, BR-97105900 Santa Maria, RS, Brazil
[5] Univ Fed Santa Maria, Ctr Cirncias Saude, Programa Posgrad Ciencias Farmaceut, BR-97105900 Santa Maria, RS, Brazil
关键词
Advanced oxidation protein products; C-reactive protein; Hypercholesterolemia; Ischemia-modified albumin; Medicinal plant; Myrtaceae; C-REACTIVE PROTEIN; CARDIOVASCULAR RISK-FACTORS; ISCHEMIA-MODIFIED ALBUMIN; CORONARY-HEART-DISEASE; REDUCTASE DEREGULATION; MYOCARDIAL-INFARCTION; NITRIC-OXIDE; CHOLESTEROL; PRODUCTS; ASSOCIATION;
D O I
10.1016/j.atherosclerosis.2014.02.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In Brazil, the edible plant Campomanesia xanthocarpa Berg. (Myrtaceae), popularly known as "guavirova," has been studied in hypercholesterolemic individuals. The present work investigated the effects of C. xanthocarpa on inflammatory processes, oxidative stress, endothelial dysfunction and lipid biomarkers in hypercholesterolemic individuals. A total of 156 individuals were selected in a double-blind fashion and randomly divided into two groups in accordance with the intervals used in the criteria for hypercholesterolemia: individuals with total cholesterol (TC) levels between 200 and 240 mg/dL (undesirable level individuals - UL) and individuals with TC levels > 240 mg/dL (hypercholesterolemic individuals e HL). Both groups had a control group (CG), which received placebo treatment, an encapsulated excipient group (lactose) and an experimental group that received 500 mg (EG 500), 750 mg (EG 750) or 1000 mg (EG 1000) of encapsulated C. xanthocarpa. The inflammatory processes (high-sensitivity C-reactive protein - hs-CRP), oxidative stress (advanced oxidation protein products-AOPPs; ischemia-modified albumin-IMA), endothelial dysfunction (nitric oxide - NOx) and biochemical (TC, triglycerides, high-density lipoprotein - HDL, low-density lipoproteins - LDL, and very low-density lipoprotein - VLDL) parameters were measured before and 90 days after the initiation of treatment. A significant decrease in TC and LDL levels was observed in HL individuals from the EG 500 group (reduction of 29 +/- 3% and 41 +/- 5% to levels before treatment) compared to the CG group individuals. A significant reduction in oxidative stress and inflammatory process components (reduction of 52 +/- 11% in AOPPs, 32 +/- 10% in IMA and 57 +/- 7% in hs-CRP) and a significant increase in NOx (increase of 84 +/- 27%) was observed in HL individuals in the EG 1000 group when compared to the CG group individuals. Treatment with encapsulated C. xanthocarpa reduced blood TC and LDL levels in hypercholesterolemic individuals. In addition to its effect on cholesterol levels, this plant reduced oxidative stress in hypercholesterolemic individuals and improved the levels of NOx. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:85 / 92
页数:8
相关论文
共 64 条
  • [1] Alice CB., 1995, PLANTAS MED USO POPU
  • [2] [Anonymous], EVIDENCE BASED COMPL
  • [3] Inflammatory biomarkers in acute coronary syndromes Part I: Introduction and cytokines
    Armstrong, EJ
    Morrow, DA
    Sabatine, MS
    [J]. CIRCULATION, 2006, 113 (06) : E72 - E75
  • [4] Treatment of high-risk older persons with lipid-lowering drug therapy
    Aronow, Wilbert S.
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2008, 15 (02) : 102 - 107
  • [5] Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men
    Austin, MA
    Rodriguez, BL
    McKnight, B
    McNeely, MJ
    Edwards, KL
    Curb, JD
    Sharp, DS
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (04) : 412 - 416
  • [6] A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia - A preliminary report
    Bar-Or, D
    Lau, E
    Winkler, JV
    [J]. JOURNAL OF EMERGENCY MEDICINE, 2000, 19 (04) : 311 - 315
  • [7] Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women
    Bermudez, EA
    Rifai, N
    Buring, J
    Manson, JE
    Ridker, PA
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (10) : 1668 - 1673
  • [8] International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
    Bhatt, DL
    Steg, PG
    Ohman, EM
    Hirsch, AT
    Ikeda, Y
    Mas, JL
    Goto, S
    Liau, CS
    Richard, AJ
    Röther, J
    Wilson, PWF
    Andersen-Dalheim, H
    Anderson, P
    Anell, B
    Arber, S
    Armstrong, K
    Arnot, D
    Baldam, A
    Barratt, I
    Barresi, S
    Beder, J
    Benson, M
    Bergman, F
    Best, J
    Bhasim, R
    Bovell, G
    Bowman, N
    Brkic, M
    Bromberger, D
    Brown, D
    Brown, J
    Brownstein, M
    Bruce, A
    Buonopane, J
    Burns, S
    Butler, A
    Byrne, D
    Carson, J
    Cassimatis, P
    Chaffey, G
    Chambers, D
    Chan, WJ
    Chan, B
    Cheatham, J
    Chen, R
    Cheong, B
    Cheung, C
    Chin, J
    Chiu, A
    Choo, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (02): : 180 - 189
  • [9] Braun TM, 2012, STAT METHODS MED RES
  • [10] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497